In turn, silencing of HDAC2 reduces the ATM/p53-mediated cell death in osteosarcoma cells after DOX treatment, which suggests that HDAC2 takes part in DNA early damage response and could be a coactivator for p53. Here, TP53 is linked to osteosarcoma.